Top Markets
#1 CyberDEX CyberDEX +372.54%
#2 OVERTAKE OVERTAKE +56.57%
#3 ALEO ALEO +43.43%
#4 Nillion Nillion +34.21%
#5 Clearpool Clearpool +27.85%
#6 Playnance Playnance +23.56%
#7 deBridge deBridge +23.20%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.17%
#9 AUKI AUKI +18.69%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.88%
Coin of the day
CyberDEX CyberDEX
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Classement en actions #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Prix de l'action
$0.05897422
Dernière synchronisation: 2024-04-02
Capitalisation boursière
$1.64M
Changement (1 jour)
0.07%
Changement (1 an)
-60.68%
Pays
CA
Échange Intellipharmaceutics International Inc. (IPCI)

Catégorie

Healthcare
Ratio P/S pour Intellipharmaceutics International Inc. (IPCI)
Ratio P/S au September 2026 TTM : 75.52
Selon les derniers rapports financiers et le cours de l'action de Intellipharmaceutics International Inc., le ratio cours/ventes actuel (TTM) est 75.52. À la fin de 2021, le ratio P/S était de 53.73.
Historique du ratio P/S pour Intellipharmaceutics International Inc. de 1999 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 75.52 114.31%
2022 35.24 -34.41%
2021 53.73 2,358.50%
2020 2.19 -5.37%
2019 2.31 151.70%
2018 0.92 -80.84%
2017 4.79 -85.55%
2016 33.15 171.91%
2015 12.19 61.06%
2014 7.57 -85.08%
2013 50.74 -86.99%
2012 390.00 315.68%
2011 93.82 375.52%
2010 19.73 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 22.45K 2.75%
2000 21.84K 14,851.44%
1999 146.10 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 -86.17%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 -65.41%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -95.03%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 -84.10%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH